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Summary
Background: Statins represent the largest selling
class of cardiovascular drug in the world. Previous
randomized trials (RCTs) have demonstrated import-
ant clinical benefits with statin therapy.
Aim:We combined evidence from all RCTs compar-
ing a statin with placebo or usual care among pa-
tients with and without prior coronary heart disease
(CHD) to determine clinical outcomes.
Design: We searched independently, in duplicate,
12 electronic databases (from inception to August
2010), including full text journal content databases,
to identify all statin versus inert control RCTs. We
included RCTs of any statin versus any non-drug
control in any populations. We abstracted data in
duplicate on reported major clinical events and ad-
verse events. We performed a random-effects
meta-analysis and meta-regression. We performed
a mixed treatment comparison using Bayesian
methods.
Results: We included a total of 76 RCTs involving
170 255 participants. There were a total of 14 878
deaths. Statin therapy reduced all-cause mortality,
Relative Risk (RR) 0.90 [95% confidence interval
(CI) 0.86–0.94, P 0.0001, I 2 = 17%]; cardiovascu-
lar disease (CVD) mortality (RR 0.80, 95% CI
0.74–0.87, P< 0.0001, I 2 = 27%); fatal myocardial
infarction (MI) (RR 0.82, 95% CI 0.75–0.91,
P< 0.0001, I2 = 21%); non-fatal MI (RR 0.74, 95%
CI 0.67–0.81, P 0.001, I2 = 45%); revasculariza-
tion (RR 0.76, 95% CI 0.70–0.81, P 0.0001); and
a composite of fatal and non-fatal strokes (0.86, 95%
CI 0.78–0.95, P=0.004, I 2 = 41%). Adverse events
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were generally mild, but 17 RCTs reported on
increased risk of development of incident diabetes
[Odds Ratio (OR) 1.09; 95% CI 1.02–1.17,
P=0.001, I2 = 11%]. Studies did not yield important
differences across populations. We did not find any
differing treatment effects between statins.
Discussion: Statin therapies offer clear benefits
across broad populations. As generic formulations
become more available efforts to expand access
should be a priority.
Introduction
For over 15 years, randomized trials of
3-hydroxymethyl-3-methylglutaryl coenzyme A re-
ductase inhibitors (statins), have evaluated their
impact on cardiovascular morbidity and overall
mortality in patients with stable coronary artery dis-
ease.1 Since then, statins have been extensively stu-
died in a large variety of patient populations
including both primary and secondary prevention
of cardiovascular disease (CVD).2,3 There is a wide-
spread interest in the use of statins for broad popu-
lations given their effectiveness and relatively
inexpensive costs now that three of them (lovastatin,
simvastatin and pravastatin) are available in generic
form. Statins are currently the largest selling pre-
scription drug worldwide and may one day be
widely available over-the-counter (OTC),4 with a
10mg tablet of simvastatin already on sale OTC in
the UK.
Clinicians have recognized that much of a statins
therapeutic effect is derived from its low-density
lipoprotein (LDL)-lowering effects.5 The greater the
LDL reduction, the greater the clinical benefit in
terms of risk reduction for CVD events.5 In addition,
there is evidence that statins, beyond their
LDL-lowering effects, reduce vascular inflammation,
improve endothelial function and decrease throm-
bus formation.6–8 The role of these so-called pleio-
tropic effects of statins is less well established and
it remains unclear if there are differences among
available statins translating into different clinical
benefit.
Large, up-to-date systematic reviews with meta-
analyses are essential to provide clinicians, health
economists and policy makers with the most reliable,
critically appraised and precise estimates of treat-
ment effects and to monitor for rare adverse events.
Therefore, we updated previous meta-analyses of
statin trials3,5,9–15 in an effort to assemble the totality
of randomized trial (RCT) evidence to date in order to
quantify the effects of statin therapy on a wide range
of clinical outcomes and populations. Our primary
outcome of interest is CVD mortality. We addition-
ally examined whether specific statins exerted
important therapeutic differences across the class of
drugs adjusted for LDL-lowering effects.
Methods
Eligibility criteria
We included any RCT of atorvastatin, fluvastatin,
lovastatin, pitavastatin, pravastatin, rosuvastatin
and simvastatin for CVD event prevention among
both primary and secondary prevention popula-
tions. We did not include cerivastatin as it has
been withdrawn from the market due to serious ad-
verse events. Studies had to compare a statin to pla-
cebo, standard therapy or no-treatment and report
on any of the following clinically important cardio-
vascular outcomes: All-cause mortality; CVD mor-
tality; fatal myocardial infarction (MI); Non-fatal MI;
major CV events (stroke, revascularization). We
excluded studies only reporting on surrogate out-
comes [e.g. LDL and high-density lipoprotein
(HDL) levels] and follow-up studies where random-
ization had been subverted.16 We additionally
excluded head–head statin evaluations.
Search strategy
In consultation with a medical librarian, we estab-
lished a search strategy (available from authors
upon request). We searched independently, in
duplicate, the following 12 databases (from inception
to August 2010): MEDLINE, EMBASE,
Cochrane CENTRAL, AMED, CINAHL, TOXNET,
Development and Reproductive Toxicology,
Hazardous Substances Databank, Psych-info and
Web of Science, databases that included the full
text of journals, ScienceDirect and Ingenta, including
articles in full text from 1700 journals since 1993).
In addition, we searched the bibliographies of pub-
lished systematic reviews3,5,9–15 and health technol-
ogy assessments.17–19 Finally, we searched our own
comprehensive rolling database of statin trials,
updated monthly. We also contacted the authors of
all trials for study clarifications, where required, and
the authors of the only individual patient data
meta-analysis of statins, that included 14 trials.5,15
Searches were not limited by language, sex or age.
Study selection
Two investigators (E.M., P.W.) working independ-
ently, in duplicate, scanned all abstracts and
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obtained the full text reports of records, that indi-
cated or suggested that the study was a RCT evalu-
ating statin therapy on the outcomes of interest. After
obtaining full reports of the candidate trials (either in
full peer-reviewed publication or press article) the
same reviewers independently assessed eligibility
from full text papers.
Data collection
The same two reviewers conducted data extraction
independently using a standardized pre-piloted
form. The reviewers collected information about
the statin and type of interventions tested, the popu-
lation studied (age, sex, underlying conditions), the
treatment effect on specified outcomes, absolute
and proportion change in LDL, HDL and total chol-
esterol and the length of follow-up. Study evaluation
included general methodological quality features,
including sequence generation, blinding, use of
intent-to-treat analysis, percentage follow-up and al-
location concealment.20 We extracted data on
the incidence of the following clinical outcomes:
all-cause mortality, CVD mortality, MI mortality,
stroke mortality, non-CVD mortality, major CVD,
MI, strokes, revascularization, cancers, rhabdomylo-
sis, diabetes, aspartate and alanine aminotransferase
(AST/ALT), and creatinine kinase (CK) increases
beyond the upper limit of normal. We entered the
data into an electronic database such that duplicate
entries existed for each study; when the two entries
did not match, we resolved differences through dis-
cussion and consensus.
Data analysis
In order to assess inter-rater reliability on inclusion
of articles, we calculated the Phi (f) statistic, which
provides a measure of inter-observer agreement in-
dependent of chance.21 We calculated the Relative
Risk [RR] and appropriate 95% Confidence Intervals
[CIs] of outcomes according to the number of events
reported in the original studies or sub-studies
intent-to-treat analyses. Where studies did not
report intent-to-treat, we analyzed outcomes as
all-patients randomized.22 In the case of an individ-
ual patient data meta-analysis of 14 trials, we
included outcomes as reported by the meta-analysis,
in correspondence with the study’s authors. In the
event of zero outcome events in one arm of a trial,
we applied the Haldane method and added 0.5 to
each arm.23 We pooled studies as an analysis of
all-statins combined using the DerSimonian–Laird
random effects method,24 which recognizes and an-
chors studies as a sample of all potential studies, and
incorporates an additional between-study compo-
nent to the estimate of variability.25 We conducted
a sensitivity analysis to determine if individual sta-
tins exerted differing effects using a mixed-treatment
comparison and also on whether baseline popula-
tion risks differed in treatment outcomes using a
Breslow–Day test.26 For adverse events, we calcu-
lated event rates using Peto’s Odds Ratio (OR).27
Peto’s odds ratios appears to provide the least
biased estimates and CI coverage with rare
events.28 Forest plots are displayed for each
all-statins analysis of our primary analyses and a
combined forest plot for secondary outcomes, show-
ing pooled estimates with 95% CIs, and the overall
DerSimmonian–Laird pooled estimate. We calcu-
lated the I2 statistic for each all-statin analysis as a
measure of the proportion of the overall variation
that is attributable to between-study heterogeneity.29
We conducted a multivariable meta-regression ana-
lysis to examine the impact of the following
co-variates, all chosen a priori: absolute LDL
change; proportion of individuals in trials that
were men; had a history of coronary heart disease
(CHD), had baseline diabetes, or were hypertensive
and current smokers.30
In order to evaluate the relative effectiveness of
each study drug on CVD mortality, we used the
Lu-Ades method for combining indirect evidence
in mixed-treatment comparisons.31 We estimated
the posterior densities for all unknown parameters
using MCMC (Markov chain Monte Carlo) for each
model. Each chain used 20 000 iterations with a
burn-in of 20 000, thin of 5 and updates varying
between 80 and 110. We used the same seed
number (SEED=314159, equivalent to 10 pi) for
all chains. The choice of burn-in was chosen ac-
cording to Gelman–Rubin approach.32 We applied
the covariate of LDL-C change and also statin
dosing (high or moderate determined by the
Canadian Compendium of Pharmaceuticals and
Specialties),33 using an approach developed by
Cooper et al.34 We assessed convergence based
on trace plots and time series plots. The accuracy
of the posterior estimates was done by calculating
the Monte Carlo error for each parameter. As a rule
of thumb, the Monte Carlo error for each parameter
of interest is less than 5% of the sample standard
deviation. All results for the mixed-treatment ana-
lysis are reported as posterior means with corres-
ponding 95% credibility intervals (CrIs). CrIs are
the Bayesian equivalent of classical CIs. We as-
sessed the fit of our model using the Deviance
Information Criterion (DIC), a measure of model fit
that penalizes model complexity. This criterion ad-
vocates selecting the model with the lowest DIC
value among a series of competing models for the
same data, as this model is believed to provide the
Statin treatment for cardiovascular disease 111
best fit to the data. DIC’s were not importantly dif-
ferent across models.
Finally, we conducted a trial sequential analysis
to determine the strength of information for our
meta-analysis on the primary outcome of CVD mor-
tality to determine the conservative number of pa-
tients required to provide an authoritative answer of
therapeutic efficacy.35 We applied a Lan–DeMets
(LD) sequential monitoring boundary that assumes
a 4% control event rate, 20% relative risk reduction,
90% power and a two-sided a=0.05. We plotted
the trial sequential analysis to display the
heterogeneity-corrected optimal information size
(HOIS). Analyses were conducted using StatsDirect
(version 2.5.2, www.statsdirect.com), Stata (version 9,
www.stata.com) and in WinBUGS version 1.4
(Medical Research Council Biostatistics Unit,
Cambridge).
Role of the funding source
No funding sources had a role in study design, data
collection, data analysis, data interpretation or writ-
ing of the report. The writing group had full access to
all the data in the study and had final responsibility
for the decision to submit for publication.
Results
We included a total of 76 RCTs meeting our inclu-
sion criteria (Figure 1). Data were available on
170 255 participants. Women represented 26%
of trial participants. The average age of included
participants was 59.6 [standard deviation (SD)
5.93], ranging from 38 to 75. Trials used four distinct
controls as an inert control. These included placebo
(52 RCTs),1,36–85 usual care (18 RCTs),8,86–102 no
treatment (four RCTs)103–106 and conventional ther-
apy (2 RCTS).89,107 Trials followed patients for an
average of 2.7 years (SD 1.60), ranging from 0.5
years to 6.1 years.40 The mean pre-treatment LDL
cholesterol was 4.61mmol/l (179.79mg/dl) and
ranged from 2.43mmol/l105 (94.77mg/dl) to
5mmol/l (195mg/dl).51 Table 1 displays the study
characteristics.
Methodological quality of included studies
We found that the reporting quality of studies varied.
Twenty-six studies reported how randomization
sequence was generated in their primary publica-
tion.1,8,37,44,45,50,52,58–60,63,64,67,71,75,76,80,82,83,85,94,
96,98,99,104,105 Eighteen studies reported on how
allocation to groups was concealed.38,59,60,63,64,
66,67,70,73,75,76,83,91,93,97,99,105,106 Most of the studies
(64) reported on loss-to-follow up1,36,38,40–
46,48–50,52,53,55–65,67,69–82,8,83–88,90–97,99–104,106–108
and only four studies37,49,78,80 reported that the pri-
mary results were based on a per-protocol analysis
rather than intent to treat. Sixty-one studies re-
ported on at least one specific group being
blinded in the trial, typically patients and care-
givers.1,8,36–52,54–56,58–62,64–91,95,96,103,106–108
All cause and cause-specific mortality
There were a total of 14 878 deaths including a total
of 7864 from confirmed vascular causes (Figure 2).
In all trials combined, there were a total of 7004
(8.1%) deaths among the 86 328 patients receiving
a statin and 7713 (9.5%) deaths among 80365 pa-
tients receiving a control intervention. Combined,
this represents a 10% reduction in all-cause mortal-
ity (RR 0.90, 95% CI 0.86–0.94, P 0.0001,
573 potentially relevant 
articles identified and 
screened for retrieval 
356 articles excluded based 
on title and abstract 
217 articles retrieved in full 
text for detailed evaluation 
139 articles excluded, for following 
reasons: 
• 12 head to head RCTs 
• 3 survival rates only 
• 9 follow up <6 months 
• 65 subgroup analysis of 
included trials or duplicate 
reporting 
• 33 evaluated outcomes of 
no interest to this analysis 
• 4 non-randomized 
• 13 rationale, study protocol 
or baseline report
78 articles addressing statin 
efficacy 
3 articles excluded, for following 
reasons: 
• 1 statin not compared with 
control 
• 2 mortality and CVD events 
not clearly reported 
76 included RCTs 
1 article reported during 
peer review period  
Figure 1. Flow diagram of included studies.
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I2 = 17%). Each 10% change in absolute LDL levels
was associated with a 1.1% (95% CI 0.3–1.19,
P=0.003) risk reduction.
The large risk reduction in all-cause mortality was
chiefly attributed to the 20% risk reduction in CVD
deaths [3605 (4.1%) of statin-treated patients vs.
4248 (5.1%) control-treated patients: RR 0.80,
95% CI 0.74–0.87, P< 0.0001, I2 = 27%].
Applying a univariate regression, each 10%
change in LDL levels was associated with a 5.6%
(95% CI 2–8%, P 0.001) risk reduction of CV
death. This effect diminished in the multivariable
analysis. Table 2 displays the impact of a priori
chosen covariates on CVD mortality.
We also found a consistent reduction in fatal MI
with an 18% risk reduction (RR 0.82, 95% CI
0.75–0.91, P< 0.0001, I2 = 21%). We found a
statistically non-significant reduction in deaths
from stroke (RR 0.92, 95% CI 0.80–1.07, P=0.55)
and in non-CVD causes (RR 0.95, 95% CI 0.90–
1.00, P=0.07).
Risk factors across underlying conditions
We assessed whether our pooling of data from all
CVD trials across disease conditions was reasonable
and divided the RCTs into their specific primary dis-
ease populations assessing CVD death. We included
42 CHD RCTs;1,8,36–51,53–58,86–97,103–108 7 athero-
sclerosis;61,66,68,69,71,79,98 11 primary preven-
tion;60,62–64,70,74,76,81,83,89,99 4 diabetic
patients;65,67,75,80 2 elderly patients; 59,72 2 renal dis-
ease; 82,101 4 transplant patient;52,73,100,102 1 previ-
ous stroke;77 2 RCTs of congestive heart failure;78,85
0.5 1.0 1.5
Statin Control  
better better 
Figure 2. Forest plot of mortality across statins.
Table 2 Meta-regression, impact of co-variates on estimates of CV death
Independent
variable n=51
Parameter (95% CI) Relative increase
in RR (95%CI)
(every 10 U increase
in predictor)
P-value R2
Intercept 0.68 (–1.14 to –0.22) – 0.005 0.45
Delta-LDL 0.001 (–0.003 to 0.005) – 0.51
Men (%) 0.001 (–0.004 to 0.007) – 0.60
Prior CHD (%) 0.002 (–0.00003 to 0.004) 2% (0–4%) 0.05
Diabetes (%) 0.003 (–0.001 to 0.007) – 0.15
Hypertension (%) 0.005 (0.002 to 0.008) 5% (2–8%) 0.0003
Current smokers (%) 0.0008 (–0.005 to 0.007) – 0.78
High dose 0.096 (–0.194 to 0.001) – 0.054
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and 1 RCT with hypercholesterolemic patients with
chronic liver disease.84 Studies did not yield an
importantly different direction of effect dependent
on populations (heterogeneity P=0.07) (Table 3).
Major cardiovascular events
There were 6318 non-fatal MIs reported in 58 RCTs
enrolling 146 041 patients.1,8,37–45,47–52,54–56,
58–63,66,67,69–77,79,81,82,84,86–94,95,97–99,101,103,107,108
Overall, there was a highly significant 26% reduc-
tion in non-fatal MI [2810 (3.6%) statin vs. 3508
(4.9%) control: RR 0.74, 95% CI 0.67–0.81,
P 0.001, I2 = 45%]. Data were also available on
revascularization from 44 RCTs enrolling 118 296
individuals.1,38–41,43,44,47–49,53–56,58–60,62,66,67,69,70,
72–77,82,87–91,93–95,98,99,101,103,106–108 We found a
highly significant effect of statins on revasculariza-
tion status [3723 (6.2%) statin vs. 4816 (8.1%) con-
trol: RR 0.76, 95% CI 0.70–0.81, P 0.0001,
I2 = 44%].
In addition to assessing fatal strokes, we evaluated
fatal and nonfatal strokes excluding transient ische-
mic events and included data from 53 RCTs enroll-
ing 154 818 individuals.8,36–38,40–44,48,50,52,54–56,
58–61,63–65,67,69–77,79,81,82,86,88–95,97–99,101,103,107,108
We found a strongly significant effect favoring sta-
tins [2201 (2.7%) statins vs. 2516 (3.4%) controls:
RR 0.86, 95% CI 0.78–0.95, P=0.004, I2 = 41%].
Due to concern that statins raise hemorrhagic
stroke risk, we evaluated the number of hemorrhagic
strokes reported in 14 RCTs enrolling 61 045 indi-
viduals.1,38,40,52,58,60,74,75,82,86,89,91,99,107 We found
a low incidence of hemorrhagic strokes [267
(0.86%) statins vs. 310 (1.03%) controls: RR 0.86,
95% CI 0.73–1.01, P=0.07, I2 = 0%], and our
analysis indicated that statins did not increase the
risk.
Impact of individual statins on CVD
mortality
We assessed the impact of individual statins on CVD
death. Figure 3 displays the geometric distribution of
the RCTs (Figure 3). We excluded one trial of mixed
statins in this analysis.97 Our analysis included
15 RCTs assessing atorvastatin (n=29931);8,45,46,
64,65,67,72,83,93–96,104,105,108 nine assessing fluvasta-
tin (n=7383);47–52,68,73,79 eight RCTs evaluating
lovastatin (n=16827);36,37,61,62,81,86,87,107 25 RCTs
evaluating pravastatin (n=51011);38–44,59,63,66,69–
71,74,84,88–92,98–100,103 five RCTs evaluating rosuvas-
tatin (n=30 245);57,58,76,82,85 and nine RCTs assess-
ing simvastatin (n=26 545).1,53–56,60,80,102,106
Mixed-treatment comparison
We applied a mixed-treatment comparison adjust-
ing for LDL-C changes. Table 4 displays the
mixed-treatment comparisons between statins. We
did not find a significant difference between any
statins. A Bayesian probability estimate suggests
that certain statins exert a minimally important dif-
ference over other statins (Table 5).
Adverse events
Data were available from 34 RCTs on first incident
cancers recorded after randomization [median
follow-up 3.9 years (interquartile range 2.6–4.9)].1,
Table 3 CVD deaths across populations in included
studies
Population RR (95% CI)
CHD 0.82 (0.76–0.88)
Atherosclerotic 0.51 (0.22–1.18)
Primary prevention 0.81 (0.75–0.87)
Diabetes 0.85 (0.70–1.03)
Elderly 0.79 (0.60–1.02)
Renal disease 1.01 (0.89–1.16)
Transplant 0.68 (0.45–1.03)
Previous stroke 1.02 (0.66–1.68)
Congestive heart failure 1.01 (0.91–1.13)
Heterogeneity P-value = 0.07.
Controls 
rosuva
simva
prava lova
fluva 
atorva 
va
5
15
9
825
9
Figure 3. Geometric distribution of network of evidence.
Geometric distribution of included RCTs in mixed-
treatment analysis. Each node in the network represents
a drug treatment and each arm is weighted by the number
of trials of that intervention versus the common control
comparator.
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37,38,40,44,47,49,50,55,58–60,62,63,66,67,69–73,75–77,80,85,
88–90,93,99–102 The incidence of cancers was not dif-
ferent between statin groups and control groups
[3860 (4.5%) vs. 3703 (4.7%): OR 0.99, 95% CI
0.94–1.04, P=0.76, I2 = 0%]. Rhabdomyolysis infor-
mation was available from 35 RCTs enrolling a
total of 135 243 individuals.1,8,37,38,40,44,47,50,55,
57–60,62,64,65,67–70,73–77,80,81,83,84,89,93,95,99,101,104
We did not find a significant difference between
groups [176 (0.25%) statins vs. 168 (0.25%) con-
trols: OR 1.04, 95% CI 0.82–1.30, P=0.73,
I2 = 0%].
We evaluated incident diabetes available from
17 RCTs enrolling 111 003 individuals.1,40,44,
58–60,64,70,74,76,88,99 62,63,85,89 When we evaluated
new incident diabetes [2215 (3.8%) statins vs.
2048 (3.5%) controls: OR 1.09; 95% CI 1.02–1.16,
P=0.008, I2 = 26%], we found a significantly
increased rate of diabetes. Finally, we examined
the impact of statins on elevated AST from
23 RCTs and found a significant association (OR
1.12, 95% CI 1.03–1.22, P=0.005); the impact of
statins on ALT increases from 18 RCTs (OR 1.30,
95% CI 1.13–1.50, P 0.001, I2 = 0%); and the
impact of statins on CK increases beyond normal
from 19 RCTs (OR 1.07, 95% CI 0.78–1.46,
P=0.66, I2 = 29%). Figure 4 graphically displays
the adverse event effect sizes.
Trial sequential monitoring
We applied the TSM evaluation to determine the
strength of inference about statins in preventing
our primary outcome, CV deaths (Figure 5). We dis-
play that based on events accumulating up to 2001,
there is conclusive evidence of CV death protection
across broad populations.
Discussion
Our meta-analysis demonstrated consistent benefits
from LDL-lowering effects attributed to statin ther-
apy. Our analysis demonstrates that statin therapy
reduces major CVD events and all-cause mortality.
Risks associated with statins appear limited to
changes in biochemical profiles rather than clinical
events, although there is now reason to explore the
extent to which statins may contribute to increased
incidence of diabetes. Reasons for possible
increased risk of developing diabetes are poorly
understood and genome-wide scans have not iden-
tified an association between genes involved in
moderating LDL cholesterol and statin
pharmacodynamics.109
There are several strengths to consider in our ana-
lysis. First, our study is the largest evaluation of sta-
tins to date. The findings of our analysis are
remarkably similar to the Cholesterol Treatment
Trialists Collaboration (CTTC), an individual patient
data meta-analysis that has now published findings
on LDL-lowering effects and outcomes among dia-
betic patients.5 While, we included 62 more RCTs
than the CTTC analysis, our analysis is based on
secondary data and we did not have access to indi-
vidual level data. We applied rigorous searching,
based on our ongoing statins database, and ex-
tracted data in such a manner as to reduce the risk
of error. We considered the strength of evidence
using trial sequential monitoring and found that
clear evidence existed in 2001 of statins in CVD
Table 4 Mixed-treatment comparison for CV deaths
Treatment comparison OR (95% Credible Interval)
Pravastatin vs. Control 0.78 (0.65–0.93)
Atorvastatin vs. Control 0.80 (0.65–0.96)
Fluvastatin vs. Control 0.61 (0.41–0.88)
Simvastatin vs. Control 0.74 (0.56–0.98)
Lovastatin vs. Control 0.73 (0.43–1.22)
Rosuvastatin vs. Control 0.88 (0.73–1.06)
Atorvastatin vs. Pravastatin 1.02 (0.79–1.33)
Fluvastatin vs. Pravastatin 0.78 (0.51–1.19)
Simvastatin vs. Pravastatin 0.95 (0.68–1.33)
Lovastatin vs. Pravastatin 0.94 (0.55–1.60)
Rosuvastatin vs. Pravastatin 1.12 (0.87–1.46)
Fluvastatin vs. Atorvastatin 0.76 (0.50–1.18)
Simvastatin vs. Atorvastatin 0.93 (0.66–1.31)
Lovastatin vs. Atorvastatin 0.91 (0.53–1.58)
Rosuvastatin vs. Atorvastatin 1.10 (0.84–1.44)
Simvastatin vs. Fluvastatin 1.22 (0.76–1.97)
Lovastatin vs. Fluvastatin 1.20 (0.63–2.27)
Rosuvastatin vs. Fluvastatin 1.44 (0.94–2.20)
Lovastatin vs. Simvastatin 0.98 (0.55–1.76)
Rosuvastatin vs. Simvastatin 1.18 (0.85–1.66)
Rosuvastatin vs. Lovastatin 1.20 (0.69–2.09)
Table 5 CVD mortality and the probability that each
treatment is associated with lowest mortality
Treatment Absolute treatment
effect (%)
Probability that
treatment is best
Control 2.37 0.000
Pravastatin 1.86 0.026
Atorvastatin 1.91 0.022
Fluvastatin 1.48 0.595
Simvastatin 1.79 0.102
Lovastatin 1.79 0.237
Rosuvastatin 2.00 0.019
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risk populations. We demonstrated a harmful effect
associated with diabetes incidence, first highlighted
in the Justification for the Use of Statins in
Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER) trial.76 A recent
meta-analysis of 13 RCTs, published while this
manuscript was under review, found an estimate
of RR 1.09 (95% CI 1.02–1.17).110 We compared
our previous search with their included studies
and added an additional seven studies to our
review, an addition of three from theirs. We modi-
fied our manuscript as a result. Finally, we applied a
mixed-treatment comparison to evaluate the relative
effectiveness of specific statins. There are also limi-
tations to consider in our analysis, mainly related to
the limitations of the included studies. As with any
meta-analysis that uses published manuscripts as the
data source, it is possible that the original papers
were poorly reported. Examples of this include
where the papers may report on all-cause mortality,
but not specific elements of the cause of death.
Similarly, manuscripts may include a composite
endpoint, for example, stroke death and non-fatal
stroke, and it is occasionally impossible to extract
0.5 1.0 1.5
Statin Control  
better better 
Figure 4. Adverse events associated with statin use in included trials.
Figure 5. Trial sequential analysis plot, CVD mortality.
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data on the individual components of the compos-
ite.111 We included only trials evaluating statins
with inert controls rather than head-to-head trials.
Previous analysis of head-to-head trials have
demonstrated that these trials evaluate dosing
rather than the effectiveness of individual sta-
tins.112–115 Our analysis of cancer trials involved a
median follow-up of 3.9 years (interquartile range
2.6–4.9). It is possible that longer periods of
follow-up would find differing effects as cancers
may take years to develop. Finally, while we
found concerning evidence of increased diabetes
incidence, this appears to be poorly monitored in
clinical trials.
Conducting meta-analyses in cardiac trials pre-
sents an important methodologic challenge. Many
cardiovascular trials use composite endpoints of
their primary endpoints, whereby they combine
various endpoints, but with little frequency of the
same endpoints among trials. For example, a trial
may report a primary composite outcome of
all-cause mortality, MI and rehospitalization. Such
an endpoint is useful for identifying a primary out-
come unlikely to occur in a clinical trial, thus con-
serving power, but is unhelpful if the authors fail to
report the individual outcomes across the composite
symptoms. We have previously reviewed the role of
composite outcomes in cardiovascular trials and
found that composite outcomes can be misleading,
as they place similar weight upon minor outcomes
(such as rehospitalization) with major outcomes
(such as all-cause mortality).111,116 We do not be-
lieve that composite outcomes of incoherent out-
comes should be pooled in a meta-analysis if the
individual components of the composite are not pro-
vided. In this study, we chose not to utilize the
common composite endpoint of coronary heart dis-
ease death plus non-fatal MI.
Our mixed-treatment comparison failed to dem-
onstrate significant differences between statins.
Previous efforts to assess differences between statins
have been based on smaller numbers of trials.2,
17–19,117 We believe that, based on using all avail-
able evidence, generic versions of statins exert simi-
lar therapeutic effects as brand-label statins, a
finding consistent across populations.2 Using a
Bayesian probability framework, it is possible that
lovastatin exerts a larger therapeutic effect.
However, for several reasons, this inference may
be weakened. Lovastatin trials had frequently smal-
ler sample sizes and were conducted predominantly
in the early 1990s, before other statin trials, when
less complex patients could be entered into the
trials, and when other concomitant therapies (i.e.
blood pressure lowering, diuretics, anticoagulants)
may have been in less frequent use compared to
more recent standards of care.
We applied the trial sequential analysis strategy to
determine the strength of inference of the cumula-
tive data on the primary endpoint. Conceptually, the
trial sequential analysis is analogous to determining
whether a single large trial is sufficiently powered
and has a sufficient number of events to warrant
stopping a trial due to conservative expectations
that a treatment effect is overwhelmingly beyond
chance. Due to heterogeneity across included trial
populations, treatments and methods, meta-analysis
sample size considerations additionally need adjust-
ment for variation across trials.35 Such adjustments
are analogous to adjustments for variation across
centers in a multi-center trial. In our analysis, we
found compelling evidence of effectiveness at ap-
proximately 2001, when 31 trials had been con-
ducted. We found that a large number of further
inert-controlled trials have been conducted since
that period. As with the mixed-treatment compari-
son, there are several considerations and possible
explanations for this phenomenon. First, as drugs
are developed and approved for use within com-
paratively uncomplex patient groups, such as sec-
ondary prevention CVD patients, trialists and drug
developers seek further opportunities to reduce the
risk of events within similar, but more complex pa-
tient groups, such as diabetic, renal and transplant
patients. Drug companies may seek additional rec-
ommendations for their drug and seek increasingly
complex patient groups, sometimes with disappoint-
ing results.58 Other drug companies may seek to
gain access to the drug market and display evidence
of similar efficacy within similar populations.
The important individual patient data meta-
analysis of 14 large trials, conducted by the CTTC
collaboration, found a 12% proportional reduction
in all-cause mortality per mmol/l reduction in LDL-C
(RR 0.88, 95% CI 0.84–0.91; P 0.0001).5 Our
study examined LDL-C reductions on CVD mortality
and found that every 10% absolute reduction in
LDL-C was associated with a 2% RR in CVD mor-
tality, consistent with the CTTC analysis. However,
in our multivariable regression analysis, this effect
was diminished. Meta-analyses by publication are
frequently limited in assessing continuous outcome
changes as we did not have the individual level
data. It is possible that if we had the individual
level data we could demonstrate larger treatment
effects associated with LDL-C and possibly HDL-C
changes.6 Our study demonstrates a clear and con-
sistent benefit of statins, regardless of product. Many
of the trials we included were conducted in
resource-limited settings. In many of these settings,
statins have been an exclusive therapy for wealthier
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individuals. As generic formulations are now avail-
able, and demonstrate consistent effects, there
should be a greater effort to expand access to ther-
apy among populations that may have previously
been unable to access them.
In conclusion, statins play an important role in
reducing clinically relevant cardiovascular out-
comes, most likely due to reducing LDL-C levels.
Current guidelines aim to establish target LDL-C re-
ductions to improve a patients long-term reduction
in clinical events. Given the clear benefits of statins,
adherence to statin therapy should now be a major
concern for physicians. Efforts to ensure adherence
may be learned from other fields of chronic diseases
health care, including reminder systems for patients
and possibly even resource intensive strategies such
as pill-counts and pharmacy refill assessments.
There are few interventions in health care that
offer such favorable outcomes and so improving
access to treatment and adherence to therapy
should be a prime concern for physicians and
public health. As statin therapy moves into generic
formulations, costs are reduced and this may open
an opportunity to share these clinically important
treatments with those who were previously
excluded due to cost.
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